Interferon-alpha in the treatment of myeloproliferative diseases.
Despite significant progress, the treatment options for myeloproliferative neoplasms (MPN) are still limited. Interferon &#945; (IFN&#945;) has been recognized as a substance for the treatment of MPN for more than 30 years, but its widespread use has been limited by higher frequency of short-term adverse reactions compared to conventional treatment and until recently, by its off-label indication in BCR/ABL negative MPNs. With the development of pegylated forms of IFN&#945; with a more favorable toxicity and pharmacokinetic profile have renewed interest in the use of IFN&#945; in the treatment of MPN. Recent studies confirm that IFN&#945; is important drug capable of reducing the tumor population in MPN. Thus, IFN&#945; is currently a more frequently considered drug in the treatment of MPN and has adop-ted into of some expert recom-mendations as a first-line drug for younger patients with various subtypes of MPN.
['Kissová|Jarmila|J|']
D000970:Antineoplastic Agents D001685:Biological Factors D006801:Humans D016898:Interferon-alpha D009196:Myeloproliferative Disorders
myeloproliferative neoplasm essential thrombocythemia interferon α pegylated interferon-α polycythemia vera primary myelofibrosis